ICMR-Serum Institute Covid vaccine completes enrolment for phase 3 trials

The Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) have announced the completion of enrolment of phase 3 clinical trials for COVISHIELD in India.

ICMR and SII have further collaborated for the clinical development of COVOVAX (Novavax) developed by Novavax, USA and upscaled by SII, according to an official release.

ICMR has funded the clinical trial site fees while SII has funded other expenses for COVISHIELD. At present, SII and ICMR are conducting Phase 2/3 clinical trial of COVISHIELD at 15 different centres, across the country. It has completed the enrolment of all 1600 participants on 31 October